This study by Paul S. Bernstein, Faisal Ahmed, Aihua Liu, Susan Allman, Xiaoming Sheng, Mohsen Sharifzadeh, Igor Ermakov, and Werner Gellermann in IOVS examined the macular pigment in AREDS2 patients. AREDS2 is a randomized, placebo-controlled study designed to determine whether supplementation with 10 mg of lutein and 2 mg of zeaxanthin per day can slow the rate of progression of age-related macular degeneration (AMD). Continue reading “Macular pigment imaging in AREDS2 participants: An ancillary study of AREDS2 subjects enrolled at the Moran Eye Center”